Merkel Cell Carcinoma (MCC) is a rare cancer most commonly affecting White patients; less is known for Black patients. We aim to report presentation, treatment, and quality of registry data by race with a secondary endpoint of overall survival. We conducted a retrospective cohort analysis between 2006–2017 via the National Cancer Database of Black and White MCC patients with and without known staging information. Multivariable logistic, proportional odds logistic, and baseline category logistic regression models were used for our primary endpoint. Multivariable Cox regression was used to interrogate overall survival. Multiple imputation was used to mitigate missing data bias. 34,503 patients with MCC were included (2566 Black patients). Black patients were younger (median age 52 vs. 72, p < 0.0001), had higher rates of immunosuppression (28% vs. 14%, p = 0.0062), and were more likely to be diagnosed at a higher stage (proportional OR = 1.41, 95% CI 1.25–1.59). No differences were noted by race across receipt of definitive resection (DR), though Black patients did have longer time from diagnosis to DR. Black patients were less likely to receive adjuvant radiation. Black patients were more likely to have missing cancer stage (OR = 1.69, CI 1.52–1.88). Black patients had decreased adjusted risk of mortality (HR 0.73, 0.65–0.81). Given the importance of registry analyses for rare cancers, efforts are needed to ensure complete data coding. Paramount to ensuring equitable access to optimal care for all is the recognition that MCC can occur in Black patients.
Testicular cancers are a common etiology for painless testicular masses occurring in young adult males between the ages of 20 and 34, with 50% diagnosed as seminomas. Seminomas are a malignant germ-cell tumor most commonly confined to the testicles with less frequent de novo involvement of structures outside of the seminiferous tubules. Radiation therapy (RT) has historically been indicated for patients with stage 1-2 seminoma, but its use is declining due to increased uptake of surveillance and modern chemotherapy. However, seminoma is a radiosensitive tumor, and RT may play a role in select cases. This case report describes a nontypical presentation of a large IIC retroperitoneal seminoma measuring 15 cm in an older patient who was a suboptimal candidate for chemotherapy. He was treated with an online adaptive external-beam radiation platform, leading to a significant reduction in body and bowel dose compared with standard-of-care radiation treatment. Clinical regression of tumor was achieved while sparing exposure to significant volumes of bowel and healthy pelvic tissue. The patient had an uneventful recovery and showed no signs of radiation dermatitis or gastrointestinal toxicity.